Fractyl Health (GUTS) Gross Margin (2023 - 2024)
Fractyl Health (GUTS) reported Gross Margin of 100.0% for Q4 2024, up 2857.0% year-on-year from 3.38% in Q1 2024, and up 100.0% quarter-over-quarter from 50.0% in Q3 2024.
Fractyl Health (GUTS) has 2 years of Gross Margin data on file, last reported at 100.0% in Q4 2024.
- For the quarter ending Q4 2024, Gross Margin rose 2857.0% year-over-year to 100.0%; the trailing twelve-month figure through Dec 2024 stood at 46.24% (up 1040.0% YoY), and the FY2024 full-year result was 46.24%, up 1040.0% from the prior year.
- Gross Margin for Q4 2024 stood at 100.0%, up from 50.0% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q4 2024 and bottomed at 30.56% in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 86.85% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 91.79% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 82.22% |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 50.00% |
| Jun 30, 2024 | 44.19% |
| Mar 31, 2024 | 42.42% |
| Dec 31, 2023 | 71.43% |
| Sep 30, 2023 | 30.56% |
| Jun 30, 2023 | 34.72% |
| Mar 31, 2023 | 40.00% |